Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing treatments for gastrointestinal diseases, particularly GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis [4] - GIMOTI is the only drug approved in the U.S. for treating gastroparesis, which affects millions globally and can lead to serious gastrointestinal symptoms and complications [5] Patent Announcement - Evoke Pharma announced the listing of U.S. Patent No. 12,377,064 for GIMOTI in the FDA's Orange Book, which covers its use in patients with moderate to severe gastroparesis symptoms [1][3] - The new patent is set to expire on November 17, 2038, extending the commercial life of GIMOTI by approximately eight years compared to the previous patent expiring on May 15, 2030 [3] Strategic Implications - The patent listing reflects Evoke's commitment to innovation and protecting its investments, aiming to maximize GIMOTI's market presence and ensure patient access to effective non-oral treatments [2][3] - The company emphasizes the importance of GIMOTI as a non-oral option for patients who struggle with oral medication absorption due to gastroparesis [3]